Company Overview

■ ■ Following successful closings of its announced acquisitions, MDCL will be the 6th largest U.S. vertically integrated cannabis operator in the nation by revenue, with positive EBITDA - a key differentiator versus the industry ■ Legacy Cannabis Aggregated significant capital at unsustainable multiples Deployed capital intensive multi-state strategies Inefficient operating structures with limited profitability Limited operating experienced management teams ($USD in millions) $300 $250 $200 $150 SIGNIFICANT OPERATOR WITH KEY DIFFERENTIATION $100 $50 ($50) ($100) ($150) ($200) $144 (3) $36 MM MEDICINE MAN TECHNOLOGIES $295 ($24) curaleaf. $209 $77 $161 ($19) Trulieve GTI $152 ($189) Last Twelve Months Revenue and EBITDA (¹) MedMen $152 ($76) ■ CRESCO LABS ■ ■ ■ Very attractive entry points Single mature state maximizes economies of scale $122 Aggregating assets with track records of revenue and profitability Current team has a track record of success working together ($125) $96 EBITDA The MDCL Difference ($83) TILT HARVEST $65 ($83) COLUMBIA CABL $64 ($153) Acreage. HOLDINGS $53 MMEDICINE MAN ($51) ¡Anthus TECHNOLOGIES $28 ($69) GREEN GROWTH BRANDS Revenue Note: Company figures are unaudited and represent the Company's current estimates. These figures are subject to adjustment and change upon completion of the audits for each of the entities included therein Source: Public company filings (1) Pro forma for publicly announced deals | (2) Revenue after elimination of $26MM of intercompany payments. PCAOB / Quality of Earnings audits currently underway, anticipated for completion April 2020 | (3) EBITDA based on mid point of Company's 20% - 30% EBITDA margin guidance 5

View entire presentation